Acute leukemias can exhibit resistance to T-cell engaging antibodies through immune evasion, via both innate and adaptive mechanisms. In this interview, Marion Subklewe, MD, of LMU-University Hospital Munich, Munich, Germany, discusses how this resistance can be combated. Dr Subklewe highlights novel combinations with T-cell engagers, including those with immune checkpoint or tyrosine kinase inhibitors. She then highlights the patients that this therapy would be ideal for, before giving her perspective on what the future of this treatment could look like. This video was recorded at the 1st International Workshop on Acute Leukemias (iwAL), held in St. Pete Beach, FL.